An article from the Wall Street Journal earlier this week points out the growing controversy over how to deal with (and whether to allow) generic versions of biotech drugs. Biotech companies argue that there's no way to engineer and deliver a generic version without all the same safety testing and regulations that went into making the original, but that hasn’t stopped companies from starting work on it -- or legislators from proposing bills allowing for these kinds of generics.
Biosimilars ... That's Catchy
Mar 17, 2007
What's Popular?